Sensei Biotherapeutics Management
Management criteria checks 2/4
Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.17 years. total yearly compensation is $1.57M, comprised of 32.7% salary and 67.3% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $62.50K. The average tenure of the management team and the board of directors is 1.5 years and 3.1 years respectively.
Key information
John Celebi
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 32.7% |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$34m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$513k | -US$49m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$7m | US$487k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$33m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$2m | US$395k | -US$20m |
Compensation vs Market: John's total compensation ($USD1.57M) is above average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Celebi (51 yo)
6.2yrs
Tenure
US$1,568,882
Compensation
Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$1.57m | 0.25% $ 62.5k | |
| Chief Scientific Officer | 1.3yrs | US$654.40k | 0.14% $ 35.4k | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| Senior VP | 1.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
1.5yrs
Average Tenure
Experienced Management: SNSE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.2yrs | US$1.57m | 0.25% $ 62.5k | |
| Independent Director | 8.3yrs | US$93.60k | 1.35% $ 339.4k | |
| Independent Chairman | 2.1yrs | US$200.08k | 0.052% $ 13.0k | |
| Independent Director | 7.3yrs | US$87.41k | 0.084% $ 21.1k | |
| Member of Immuno-Oncology Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 3.3yrs | US$81.61k | 0.018% $ 4.5k | |
| Independent Director | 3yrs | US$79.03k | 0.018% $ 4.5k | |
| Independent Director | 4.3yrs | US$88.93k | no data | |
| Member of Immuno-Oncology Advisory Board | no data | no data | no data | |
| Member of Immuno-Oncology Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 2.8yrs | US$75.03k | 0.018% $ 4.5k | |
| Member of Immuno-Oncology Advisory Board | no data | no data | no data |
3.1yrs
Average Tenure
59yo
Average Age
Experienced Board: SNSE's board of directors are considered experienced (3.1 years average tenure).